Literature DB >> 2640985

Buprenorphine suppresses cocaine self-administration in rhesus monkeys.

N K Mello1, J H Mendelson, M P Bree, S E Lukas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2640985

Source DB:  PubMed          Journal:  NIDA Res Monogr        ISSN: 1046-9516


× No keyword cloud information.
  5 in total

1.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

Review 2.  The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.

Authors:  Nurulain T Zaveri
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.

Authors:  T V Khroyan; J Wu; W E Polgar; G Cami-Kobeci; N Fotaki; S M Husbands; L Toll
Journal:  Br J Pharmacol       Date:  2014-11-05       Impact factor: 8.739

4.  Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats.

Authors:  Giordano de Guglielmo; Alessandra Matzeu; Jenni Kononoff; Julia Mattioni; Rémi Martin-Fardon; Olivier George
Journal:  J Pharmacol Exp Ther       Date:  2017-06-23       Impact factor: 4.030

5.  Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.

Authors:  Taline V Khroyan; Willma E Polgar; Faming Jiang; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2009-08-27       Impact factor: 4.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.